Nadiesda Costa is a Nephrology physician. OpenAlex indexes 25 publications with 217 citations (h-index 9).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
22 S Greene St
Baltimore, MD 212011544
Telephone
410-328-5720Registry record last updated 8 Mar 2013.
Industry payments
11 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Eurofins Viracor, LLCProgram year20251 payment
- Travere Therapeutics, Inc.Program year20251 payment
- Veloxis Pharmaceuticals, Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
37.1%Corticosteroid15.6%Prednisone100%Part D≥17 patientsH2 blocker12.2%Famotidine100%Part D≥11 patients+ 1 more class in this area
Cardiovascular
36.1%Calcium channel blocker19.5%Nifedipine Er73%Amlodipine Besylate28%Part D<11 patientsBeta blocker16.6%Carvedilol100%Part D≥13 patientsCancer & immunology
11.7%Calcineurin inhibitor11.7%Tacrolimus100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Induction of immune tolerance in living related human leukocyte antigen–matched kidney transplantation: A phase 3 randomized clinical trial
American Journal of Transplantation
2025 - Donor-derived cell-free DNA significantly improves rejection yield in kidney transplant biopsies
American Journal of Transplantation
2025 - Improving the histologic detection of donor-specific antibody-negative antibody-mediated rejection in kidney transplants
American Journal of Transplantation
2025 - Defining Relationships Among Tests for Kidney Transplant Antibody-Mediated Rejection
Kidney International Reports
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Giuseppe Remuzzi
Mario Negri Institute for Pharmacological Research
Marcello Tonelli
University of Calgary
Johan Ärnlöv
Dalarna University
Juan Jesús Carrero
Danderyds sjukhus
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”